LCLA Stock Overview
Develops, manufactures, and trades in pharmaceutical products in Indonesia. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for LCLA from our risk checks.
PT Kalbe Farma Tbk. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp0.081 |
| 52 Week High | Rp0.094 |
| 52 Week Low | Rp0.005 |
| Beta | 0.24 |
| 11 Month Change | -7.43% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1,025.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| LCLA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.2% | -1.0% | 0.2% |
| 1Y | n/a | -19.3% | 8.5% |
Return vs Industry: Insufficient data to determine how LCLA performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LCLA performed against the German Market.
Price Volatility
| LCLA volatility | |
|---|---|
| LCLA Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: LCLA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine LCLA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 12,924 | . Vidjongtius | www.kalbe.co.id |
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through four divisions: Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business; and E-health products.
PT Kalbe Farma Tbk. Fundamentals Summary
| LCLA fundamental statistics | |
|---|---|
| Market cap | €4.10b |
| Earnings (TTM) | €186.34m |
| Revenue (TTM) | €1.94b |
22.0x
P/E Ratio2.1x
P/S RatioIs LCLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LCLA income statement (TTM) | |
|---|---|
| Revenue | Rp32.13t |
| Cost of Revenue | Rp19.91t |
| Gross Profit | Rp12.21t |
| Other Expenses | Rp9.13t |
| Earnings | Rp3.08t |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 66.74 |
| Gross Margin | 38.02% |
| Net Profit Margin | 9.59% |
| Debt/Equity Ratio | 3.0% |
How did LCLA perform over the long term?
See historical performance and comparison